Clinical trials: ARDS: Acute Respiratory Distress Syndrome
Prone Positioning, High Flow Nasal Cannula
Early PP With HFNC Versus HFNC in COVID-19 Induced Moderate to Severe ARDS
Coronavirus disease 2019 (COVID-19) is an emerging infectious disease that was first reported in Wuhan, China, and had subsequently spread worldwide. Twenty-nine percent of COVID-19 patients may develop ARDS.
- Conditions
- Prone Positioning, High Flow Nasal Cannula, Acute Respiratory Distress Syndrome, Corona Virus Infection
- Trial name
- NCT04325906
- Testing
- high flow nasal cannula (HFNC), Prone positioning (PP)
- Where
- United States
- Volunteers
- 224 people
- Sponsor
- Rush University Medical Center
Acute Respiratory Distress Syndrome
Human Mesenchymal Stem Cells For Acute Respiratory Distress Syndrome
This is a Phase 1, open label, dose escalation, multi-center clinical trial of Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells (hMSCs) for the treatment of Acute Respiratory Distress Syndrome (ARDS).
- Trial name
- START (NCT01775774)
- Testing
- Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells
- Where
- 4 sites in United States
- Volunteers
- 9 people
- Sponsor
- Michael A. Matthay
COVID-19 Pneumonia, Acute Lung Injury
Clinical Trial to Evaluate CERC-002 in Adults With COVID-19 Pneumonia and Acute Lung Injury
The study is a prospective, randomized, placebo-controlled, double-blind phase 2 clinical study of the efficacy and safety of CERC-002, a potent inhibitor of LIGHT (Lymphotoxin-like, exhibits Inducible expression, and competes…
- Conditions
- COVID-19 Pneumonia, Acute Lung Injury, ARDS
- Trial name
- NCT04412057
- Testing
- CERC-002
- Where
- 11 sites in United States
- Volunteers
- 88 people
- Sponsor
- Aevi Genomic Medicine, LLC, a Cerecor company
Acute Respiratory Distress Syndrome
Sigh Ventilation to Increase Ventilator-Free Days in Victims of Trauma at Risk for Acute Respiratory Distress Syndrome
A randomized, concurrent controlled trial to assess if adding sigh breaths to usual invasive mechanical ventilation of victims of trauma who are at risk of developing ARDS will decrease the number of days they require invasive…
- Trial name
- SiVent (NCT02582957)
- Testing
- Sigh breaths
- Where
- 15 sites in United States
- Volunteers
- 524 people
- Sponsor
- University of Minnesota
Acute Respiratory Distress Syndrome (ARDS)
LIPS-B: Lung Injury Prevention Study With Budesonide and Beta
This study tested whether inhaled budesonide and formoterol were able to alleviate or prevent pulmonary injury when administered early in hospital course to the patients at risk for developing acute respiratory distress syndrome…
- Trial name
- LIPS-B (NCT01783821)
- Testing
- Budesonide, Formoterol
- Where
- 5 sites in United States
- Volunteers
- 61 people
- Sponsor
- Mayo Clinic
Corona Virus Infection, Acute Respiratory Distress Syndrome
Losartan for Patients With COVID-19 Requiring Hospitalization
This is a multi-center, double-blinded study of COVID-19 infected patients requiring inpatient hospital admission randomized 1:1 to daily Losartan or placebo for 7 days or hospital discharge.
- Conditions
- Corona Virus Infection, Acute Respiratory Distress Syndrome, SARS-CoV Infection
- Trial name
- NCT04312009
- Testing
- Losartan
- Where
- 13 sites in United States
- Volunteers
- 205 people
- Sponsor
- University of Minnesota
SARS-CoV-2 (COVID-19) Severe Pneumonia
Study to Evaluate the Safety and Efficacy of ATYR1923 (Efzofitimod) In Participants With Severe Pneumonia Related to COVID-19
To evaluate the safety and preliminary efficacy of efzofitimod, compared to placebo matched to efzofitimod, in hospitalized participants with SARS-CoV-2 (COVID-19) severe pneumonia not requiring mechanical ventilation.
- Trial name
- NCT04412668
- Testing
- Efzofitimod 1 mg/kg, Efzofitimod 3 mg/kg
- Where
- 10 sites in United States, Puerto Rico
- Volunteers
- 36 people
- Sponsor
- aTyr Pharma, Inc.
Acute Respiratory Distress Syndrome
KL₄Surfactant Treatment in Patients With ARDS
Lung wash with KL₄Surfactant of individual lung segments using a bronchoscope compared to usual care alone consisting primarily of assisted (mechanical) ventilation in patients with acute respiratory distress syndrome(ARDS).
- Trial name
- NCT00215553
- Testing
- A.1 Lucinactant, B.3 SoC, A.2 Lucinactant
- Where
- United States
- Volunteers
- 124 people
- Sponsor
- Windtree Therapeutics
Respiratory Distress Syndrome, Adult, Sepsis
Early Insulin and Development of ARDS
Acute Lung Injury/Acute Respiratory Distress Syndrome (ALI/ARDS) is a severe lung condition that causes respiratory failure. Symptoms usually develop within 24 to 48 hours of an original injury or illness, and people with…
- Conditions
- Respiratory Distress Syndrome, Adult, Sepsis, Hyperglycemia
- Trial name
- NCT00605696
- Testing
- Insulin
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Albert Einstein College of Medicine
Mechanical Ventilation, Acute Respiratory Distress Syndrome
Retrospective Review of Mechanically Ventilated Patients Using a Continuous Data Collection System.
Today, the electronic medical record, microprocessor mechanical ventilators, and physiologic monitoring are under-utilized when translating research into decision support.
- Conditions
- Mechanical Ventilation, Acute Respiratory Distress Syndrome, Hypoxic Respiratory Failure
- Trial name
- T3 (NCT02184208)
- Where
- United States
- Volunteers
- 278 people
- Sponsor
- Boston Children's Hospital
ARDS
Extracorporeal Membrane Oxygenation (ECMO) in Non-intubated Patients With Acute Respiratory Distress Syndrome (ARDS)
Proof-of-concept study addressing the feasibility of awake ECMO (v/v) in patients with acute respiratory failure
- Trial name
- NCT01669863
- Testing
- ECMO, ECMO in non-intubated patients
- Where
- Germany
- Volunteers
- 6 people
- Sponsor
- Hannover Medical School
COVID-19
Zilucoplan® in Improving Oxygenation, Short-, Longterm Outcome of COVID19 Patients With Acute Hypoxic Respiratory Failure
The study is a randomized controlled, open-label trial comparing subcutaneous Zilucoplan® with standard of care to standard of care alone.
- Trial name
- ZILU-COV (NCT04382755)
- Testing
- Zilucoplan®
- Where
- 9 sites in Belgium
- Volunteers
- 81 people
- Sponsor
- University Hospital, Ghent
SARS-CoV Infection
Do Angiotensin Receptor Blockers Mitigate Progression to Acute Respiratory Distress Syndrome With SARS-CoV-2 Infection
The purpose of this research is to identify whether or not Angiotensin Receptor Blockers (ARB) can halt the progression to respiratory failure requiring transfer into the intensive care unit (ICU), as well as halt mechanical…
- Trial name
- NCT04340557
- Testing
- Losartan
- Where
- 3 sites in United States
- Volunteers
- 31 people
- Sponsor
- Sharp HealthCare
Acute Respiratory Distress Syndrome
LIPS-A: Lung Injury Prevention Study With Aspirin
The primary hypothesis was that early aspirin administration will decrease the rate of developing acute lung injury during the first 7 days after presentation to the hospital.
- Trial name
- NCT01504867
- Testing
- Aspirin, Lactose powder
- Where
- 16 sites in United States
- Volunteers
- 400 people
- Sponsor
- Mayo Clinic
Respiratory Distress Syndrome, Adult
Treprostinil Sodium Inhalation for Patients At High Risk for ARDS
Acute Respiratory Distress Syndrome (ARDS) is a rapidly progressing lung disease caused by a number of factors including pneumonia, sepsis and acute trauma that leads to reduced lung function and breathlessness.
- Trial name
- NCT02370095
- Testing
- Treprostinil Inhalation Solution
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of North Carolina, Chapel Hill
SARS-CoV Infection
VERU-111 in the Treatment of SARS-Cov-2 Infection by Assessing Its Effect on the Proportion of Patients Who Die on Study
To demonstrate the efficacy of VERU-111 in the treatment of SARS-Cov-2 Infection by assessing its effect on the proportion of patients who die on study (prior to Day 60).
- Trial name
- VERU-111 (NCT04842747)
- Testing
- VERU-111
- Where
- 58 sites in United States, Argentina and 4 more
- Volunteers
- 204 people
- Sponsor
- Veru Inc.
Acute Lung Injury (ALI), ARDS
Electrical Impedance Tomography (EIT) Monitoring in Adults With ALI or ARDS
Electrical impedance tomography (EIT) monitoring has been researched as a method to determine the spatial impedance distribution in a body cross section, but has yet to become an established clinical tool.
- Trial name
- NCT01272882
- Testing
- Electrical Impedance Tomography monitoring
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Christiana Care Health Services
Acute Lung Injury, Acute Respiratory Distress Syndrome
The Role of Circulating Soluble CD74 in Acute Lung Injury
Efforts to identify circulating factors that predict severity of acute lung injury/acute respiratory distress syndrome（ALI/ARDS） patients is unrevealing.
- Trial name
- NCT02201446
- Where
- China
- Volunteers
- 139 people, healthy volunteers welcome
- Sponsor
- Changhai Hospital
COVID, Corona Virus Infection
hCT-MSCs for COVID19 ARDS
This is a 50 patient, Phase 1/2a multi-center pilot study to test the safety and to describe the preliminary efficacy of intravenous administration of allogenic human cord tissue mesenchymal stromal cells (hCT-MSC) as an…
- Conditions
- COVID, Corona Virus Infection, COVID19
- Trial name
- NCT04399889
- Testing
- Human cord tissue mesenchymal stromal cells (hCT-MSC) manufactured by Duke University.
- Where
- 5 sites in United States
- Volunteers
- 12 people
- Sponsor
- Joanne Kurtzberg, MD
Acute Lung Injury
Intensive Nutrition in Acute Respiratory Distress Syndrome (ARDS): A Clinical Trial (INTACT)
The investigators propose a prospective randomized clinical trail to evaluate the impact of intensive medical nutrition therapy (IMNT) in patients with acute respiratory distress syndrome (ARDS) or acute lung injury (ALI) on…
- Trial name
- INTACT (NCT01921101)
- Testing
- intensive medical nutrition, control
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- University of Illinois Chicago